权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Chronic Kidney Disease Precision Medicine Project

慢性肾脏病精准医疗项目

基本信息

批准号：
9911026
负责人：
ROBERT Daniel TOTO
金额：
$ 30万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-15 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9911026
关键词：
Affect Atlases Biological Factors Biopsy Blood Caring Cessation of life Characteristics Chronic Kidney Failure Clinical Clinical Data Clinical Research Clinical Research Protocols Clinical Trials Cohort Studies Communities Consent Coupled Data Diabetes Mellitus Diagnosis Education Electronic Health Record End stage renal failure Enrollment Ensure Ethics Evaluation Functional Magnetic Resonance Imaging Funding Future Health Health Resources Healthcare Systems Hospitals Hypertension Image Individual Informatics Information Technology Informed Consent Infrastructure Intervention Kidney Kidney Failure Knowledge Longitudinal cohort study Medical Economics Methodology Modeling Multicenter Studies National Institute of Diabetes and Digestive and Kidney Diseases Outcome Outcomes Research Participant Patient Care Patient Recruitments Patient-Focused Outcomes Patients Phase Phenotype Population Precision Medicine Initiative Probability Process Process Assessment Prospective Studies Prospective cohort study Protocols documentation Public Health Research Research Personnel Resources Safety Sampling Site Socioeconomic Factors System Texas Time Tissues United States National Institutes of Health Urine Work base clinical phenotype clinical practice cohort collaboratory disorder subtype experience high risk improved informatics tool innovation kidney biopsy novel patient oriented patient population personalized care phenotypic data pragmatic trial precision medicine primary outcome programs radiologist recruit single photon emission computed tomography socioeconomics sound systems research therapeutic target tool translational medicine

项目摘要

The current understanding of the pathophysiologic and socio-economic processes that initiate CKD and the paths by which they progress to ESRD are poorly understood, resulting in limited treatments. There is a compelling unmet need for prospective studies to accurately phenotype patients with CKD using a combination of kidney biopsy, clinical, biologic, and socioeconomic factors to develop individualized care to improve patient outcomes. We are currently conducting the largest pragmatic trial in CKD sponsored by the NIH Collaboratory for Health Care Systems (HCS) Research using novel electronic health records (EHR) - based informatics to identify and facilitate care for patients with CKD, diabetes and hypertension, including large numbers of underserved patients. We now propose a prospective cohort study (Precise-CKD) in patients with CKD as part of the Kidney Precision Medicine Program (KPMP). We hypothesize that our large and diverse HCS will successfully obtain kidney biopsies, biosamples and clinical data from patients with CKD and that with that approach we will identify disease subgroups and contribute to the creation of a kidney tissue atlas as part of the KPMP. In the Planning Phase UG 3 of this proposal we will use our existing, fully functioning, novel information technology tools leveraging our electronic health record systems to identify, recruit, enroll and obtain clinical data, biosamples and kidney biopsies from patients with CKD-Diabetes and CKD-Hypertension from 3 large HCS. We will engage community and patient stakeholders to develop ethically-sound, patient-centered processes to engage patients with CKD in the study and obtain consent for kidney biopsies. We will work closely with KPMP to develop common study protocols and following maximum safety precautions we will obtain high quality kidney biopsies from 40 patients. In the Implementation Phase UH3 we will increase recruitment and obtain kidney biopsies, biosamples and clinical data from an additional 400 patients with CKD-diabetes and CKD-HTN adding another large HCS. We will also expand the cohort of CKD patients likely to yield actionable results based on high risk for progression (eGFR decline >30% over 2 years), novel imaging findings (fMRI or SPECT from UTSW) or results from other KPMP investigators from UG3 suggesting probability of identifying therapeutic targets. The long-standing successful track record of our group in recruiting patients into clinical trials of CKD, the large, and diverse patient populations available for recruitment at our site, the fully functioning infrastructure for identifying and recruiting patients from multiple healthcare systems with novel informatics tools, and the ethically rigorous approach to consenting for kidney biopsy coupled with the rigorously safe methodology will facilitate our efforts to contribute to the KPMP.

目前对CKD发病的病理生理和社会经济过程的理解